Compare DBI & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DBI | CABA |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.2M | 319.6M |
| IPO Year | 2005 | 2019 |
| Metric | DBI | CABA |
|---|---|---|
| Price | $6.96 | $3.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $7.25 | ★ $14.57 |
| AVG Volume (30 Days) | 679.8K | ★ 2.9M |
| Earning Date | 03-10-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $3,009,262,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | $31.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.18 | $0.99 |
| 52 Week High | $8.75 | $3.78 |
| Indicator | DBI | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 60.30 |
| Support Level | $6.25 | $2.11 |
| Resistance Level | $7.59 | $3.34 |
| Average True Range (ATR) | 0.43 | 0.29 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 42.02 | 59.77 |
Designer Brands Inc is a designer, producer, and retailer of footwear and accessories. The company operates in three reportable segments: the U.S. Retail segment, the Canada Retail segment and the Brand Portfolio segment. The U.S. Retail segment operates the DSW Designer Shoe Warehouse banner through its direct-to-consumer U.S. stores and e-commerce site. The Canada Retail segment operates The Shoe Company and DSW banners through its direct-to-consumer Canada stores and e-commerce sites. The Brand Portfolio segment earns revenue from the sale of wholesale products to retailers, commissions for serving retailers as the design and buying agent for products under private labels, and the sale of branded products through its direct-to-consumer e-commerce sites.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.